help button home button Am J Pathol Epitomics, Inc.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, A. Y.
Right arrow Articles by True, L. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, A. Y.
Right arrow Articles by True, L. D.
(American Journal of Pathology. 2004;165:1543-1556.)
© 2004 American Society for Investigative Pathology

Heterogeneity in Primary and Metastatic Prostate Cancer as Defined by Cell Surface CD Profile

Alvin Y. Liu*, Martine P. Roudier* and Lawrence D. True{dagger}

From the Department of Urology* and the Department of Pathology,{dagger} University of Washington, Seattle, Washington

Cluster designation (CD) antigens are cell surface markers that can be used to identify constituent cell populations of an organ. We have previously determined the CD phenotype of normal prostate parenchymal cells (Am J Pathol 2002, 160:37–43) and are now extending this analysis to prostate cancer. Since expression of CD antigens is associated with cellular differentiation, cancer cells may differ from their normal counterpart in their CD profile. Compared with luminal secretory cells, prostate adenocarcinoma cells are frequently negative for CD10 and CD13, express increased levels of the cell activation molecule CD24, and decreased levels of the apoptosis-associated multifunctional enzyme CD38. Expression of CD57, CD63, CD75s, CD107a, CD107b, CD164, and CD166 by cancer cells is similar to that of secretory cells. Prostate basal epithelial cells do not express the CD antigens characteristic of prostate secretory cells; and the basal cell CD markers, CD29, CD44, CD49b, CD49f, CD104, and nerve growth factor receptor (NGFR) are not expressed by cancer cells. The preferential expression of secretory cell-associated CD markers by prostate cancer cells suggests a closer lineage relationship between cancer cells and secretory cells than basal cells. Although the above cancer CD phenotype was the most frequently seen, some prostate cancers contained populations of CD10- and/or CD13-positive cells, and CD57-negative cells. Furthermore, the cancer phenotype of tumor metastasis is different. Despite its low frequency in primary tumors, CD10 is expressed by virtually all of the nodal metastases of prostate cancer. In addition, stromal fibromuscular cells associated with primary prostate cancer differ from stromal cells in benign prostate tissue by an increased level of expression of the cell activation molecule, CD90. In summary, our data show that the CD marker expression profile of prostate cancer cells most closely resembles that of secretory prostate epithelial cells and that some prostate cancers consist of heterogeneous cell populations as distinguished by CD-marker expression profiles.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. Fleischmann, T. Schlomm, H. Huland, J. Kollermann, P. Simon, M. Mirlacher, G. Salomon, F. H.K. Chun, T. Steuber, R. Simon, et al.
Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients
Clin. Cancer Res., December 1, 2008; 14(23): 7838 - 7842.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Niu, S. Altuwaijri, S. Yeh, K.-P. Lai, S. Yu, K.-H. Chuang, S.-P. Huang, H. Lardy, and C. Chang
Targeting the stromal androgen receptor in primary prostate tumors at earlier stages
PNAS, August 26, 2008; 105(34): 12188 - 12193.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S.-L. Lin, D. Chang, A. Chiang, and S.-Y. Ying
Androgen receptor regulates CD168 expression and signaling in prostate cancer
Carcinogenesis, February 1, 2008; 29(2): 282 - 290.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
T. Reiner, A. de las Pozas, R. Parrondo, and C. Perez-Stable
Progression of Prostate Cancer from a Subset of p63-Positive Basal Epithelial Cells in FG/Tag Transgenic Mice
Mol. Cancer Res., November 1, 2007; 5(11): 1171 - 1179.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Roth, D. C. Drummond, F. Conrad, M. E. Hayes, D. B. Kirpotin, C. C. Benz, J. D. Marks, and B. Liu
Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells
Mol. Cancer Ther., October 1, 2007; 6(10): 2737 - 2746.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S.-L. Lin, D. Chang, and S.-Y. Ying
Hyaluronan stimulates transformation of androgen-independent prostate cancer
Carcinogenesis, February 1, 2007; 28(2): 310 - 320.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
H. Zhang, A. Y. Liu, P. Loriaux, B. Wollscheid, Y. Zhou, J. D. Watts, and R. Aebersold
Mass Spectrometric Detection of Tissue Proteins in Plasma
Mol. Cell. Proteomics, January 1, 2007; 6(1): 64 - 71.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Nadiminty, W. Lou, S. O. Lee, F. Mehraein-Ghomi, J. S. Kirk, J. M. Conroy, H. Zhang, and A. C. Gao
Prostate-Specific Antigen Modulates Genes Involved in Bone Remodeling and Induces Osteoblast Differentiation of Human Osteosarcoma Cell Line SaOS-2
Clin. Cancer Res., March 1, 2006; 12(5): 1420 - 1430.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Society for Investigative Pathology.